A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

Screening for prostate cancer using a blood test likely reduces the risk of dying from prostate cancer and may also reduce the risk of dying from any cause. Screening likely makes little to no ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

Q: I am 84 years old and just got a new doctor. When I asked her about the prostate exam my previous doctor did every few years, she seemed dismissive, saying, “Oh, we don’t do that anymore.” Is this ...

This article was reviewed by Darragh O’Carroll, MD. Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting screened regularly for prostate cancer ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

ATLANTA - Each year, millions of American men get a blood test known as a PSA, or prostate-specific antigen, test as part of their yearly checkup. PSA is a protein produced by the prostate gland. If a ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...